Ontology highlight
ABSTRACT:
SUBMITTER: Ohta S
PROVIDER: S-EPMC3908364 | biostudies-literature | 2014 Jan
REPOSITORIES: biostudies-literature
Ohta Shuji S Tsuru Tomomi T Terao Kimio K Mogi Seiji S Suzaki Midori M Shono Eisuke E Ishida Yoshimasa Y Tarumi Eriko E Imai Masato M
Journal of clinical pharmacology 20131012 1
A multicenter, open-label, dose-escalation phase 1/2 study was undertaken to evaluate the optimal subcutaneous tocilizumab dose that would result in exposure comparable to the intravenous tocilizumab 8-mg/kg approved dose in patients with rheumatoid arthritis. A pharmacokinetic and biomarker approach was used to estimate the clinical optimal dose regimen of subcutaneous tocilizumab. Safety and efficacy of subcutaneous tocilizumab were assessed as secondary end points. Patients received subcutane ...[more]